Survey to Assess Why People Are Not Responding to Treatment in Hypertension

Bayer logo

Bayer

Status

Completed

Conditions

Arterial Hypertension

Treatments

Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01071681
14675
BI INTENS (Other Identifier)
KL0911FR (Other Identifier)

Details and patient eligibility

About

This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients

Enrollment

1,589 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Men or women over 18
  • Hypertensive patients
  • Uncontrolled hypertension (blood pressure >/=140/90 mmHg on the day of consultation or >/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure >/=150 mmHg (in the absence of orthostatic hypotension)
  • Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
  • Patients examined in common medical care practice, whatever the reason for consultation
  • Patients informed of the study

Trial design

1,589 participants in 1 patient group

Group 1
Treatment:
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems